Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats

References

• Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II—editorial review. Curr Opin Nephrol Hypertens 2005; 14: 125–131
   PubMed Web of Science ®Google Scholar
• de Champlain J, Wu R, Girouard H, Karas M, El Midaoui A, Laplante MA, Wu L. Oxidative stress in hypertension. Clin Exp Hypertens 2004; 26: 593–601
   PubMed Web of Science ®Google Scholar
• Virdis A, Schiffrin EL. Vascular inflammation: a role in vascular disease in hypertension?. Curr Opin Nephrol Hypertens 2003; 12: 181–187
   PubMed Web of Science ®Google Scholar
• Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572–575
   PubMed Web of Science ®Google Scholar
• Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM, Frolich JC. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10: 594–600
   PubMed Web of Science ®Google Scholar
• Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88: 2510–2516
   PubMed Web of Science ®Google Scholar
• Beckman J, Beckman T, Chen J, Marshall P, Freeman B. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxyde. Proc Natl Acad Sci USA 1990; 87: 1620–1624
   PubMed Web of Science ®Google Scholar
• Sanz-Rosa D, Oubina MP, Cediel E, de Las Heras N, Vegazo O, Jimenez J, Lahera V, Cachofeiro V. Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am J Physiol Heart Circ Physiol 2005; 288: H111–H115
   PubMed Web of Science ®Google Scholar
• Ni W, Kitamoto S, Ishibashi M, Usui M, Inoue S, Hiasa K, Zhao Q, Nishida K, Takeshita A, Egashira K. Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 2004; 24: 534–539
   PubMedGoogle Scholar
• Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension 2002; 39: 777–780
   PubMed Web of Science ®Google Scholar
• Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: III39–III43
   PubMed Web of Science ®Google Scholar
• Egashira K, Koyanagi M, Kitamoto S, Ni W, Kataoka C, Morishita R, Kaneda Y, Akiyama C, Nishida KI, Sueishi K, Takeshita A. Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis. Faseb J 2000; 14: 1974–1978
   PubMedGoogle Scholar
• Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 2000; 294: 1043–1046
   PubMed Web of Science ®Google Scholar
• Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002; 22: 1524–1534
   PubMed Web of Science ®Google Scholar
• Stalker TJ, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol 2001; 133: 406–412
   PubMed Web of Science ®Google Scholar
• Sicard P, Lauzier B, Oudot A, Busseuil D, Collin B, Duvillard L, Moreau D, Vergely C, Rochette L. A treatment with rosuvastatin induced a reduction of arterial pressure and a decrease of oxidative stress in spontaneously hypertensive rats]. Arch Mal Coeur Vaiss 2005; 98: 804–808
   PubMedGoogle Scholar
• Susic D, Varagic J, Ahn J, Slama M, Frohlich ED. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 2003; 42: 1091–1097
   PubMed Web of Science ®Google Scholar
• Otto A, Fontaine D, Fontaine J, Berkenboom G. Rosuvastatin treatment protects against nitrate-induced oxidative stress. J Cardiovasc Pharmacol 2005; 46: 177–184
   PubMedGoogle Scholar
• Mooradian AD, Haas MJ, Batejko O, Hovsepyan M, Feman SS. Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of streptozotocin-induced diabetic rats. Diabetes 2005; 54: 2977–2982
   PubMedGoogle Scholar
• Korandji C, Zeller M, Guilland JC, Vergely C, Sicard P, Duvillard L, Gambert P, Moreau D, Cottin Y, Rochette L. Asymmetric dimethylarginine (ADMA) and hyperhomocysteinemia in patients with acute myocardial infarction. Clin Biochem 2007; 21(2)173–180
   Google Scholar
• Kim CH, Vaziri ND. Hypertension promotes integrin expression and reactive oxygen species generation by circulating leukocytes. Kidney Int 2005; 67: 1462–1470
   PubMedGoogle Scholar
• Sicard P, Acar N, Gregoire S, Lauzier B, Bron AM, Creuzot-Garcher C, Bretillon L, Vergely C, Rochette L. Influence of rosuvastatin on the NAD(P)H oxidase activity in the retina and electroretinographic response of spontaneously hypertensive rats. Br J Pharmacol 2007; 151: 979–986
   PubMed Web of Science ®Google Scholar
• Sicard P, Oudot A, Guilland JC, Moreau D, Vergely C, Rochette L. Dissociation between vascular oxidative stress and cardiovascular function in Wistar Kyoto and spontaneously hypertensive rats. Vascul Pharmacol 2006; 45: 112–121
   PubMedGoogle Scholar
• Sagar S, Kallo IJ, Kaul N, Ganguly NK, Sharma BK. Oxygen free radicals in essential hypertension. Mol Cell Biochem 1992; 111: 103–108
   PubMed Web of Science ®Google Scholar
• Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047–1052
   PubMed Web of Science ®Google Scholar
• Boger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006; 38: 126–136
   PubMed Web of Science ®Google Scholar
• Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ J 2001; 65: 775–778
   PubMedGoogle Scholar
• Boger RH, Bode-Boger SM, Tsao PS, Lin PS, Chan JR, Cooke JP. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000; 36: 2287–2295
   PubMed Web of Science ®Google Scholar
• Wells SM, Holian A. Asymmetric dimethylarginine induces oxidative and nitrosative stress in murine lung epithelial cells. Am J Respir Cell Mol Biol 2007; 36: 520–528
   PubMed Web of Science ®Google Scholar
• MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, Whitley GS, Vallance P. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1533–1540
   PubMed Web of Science ®Google Scholar
• Wakino S, Hayashi K, Tatematsu S, Hasegawa K, Takamatsu I, Kanda T, Homma K, Yoshioka K, Sugano N, Saruta T. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 2005; 28: 255–262
   PubMed Web of Science ®Google Scholar
• Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004; 95: 858–866
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868–874
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004; 116(Suppl 6A)9S–16
   PubMed Web of Science ®Google Scholar
• Matsumori A, Sasayama S. The role of inflammatory mediators in the failing heart: immunomodulation of cytokines in experimental models of heart failure. Heart Fail Rev 2001; 6: 129–136
   PubMedGoogle Scholar
• Ishibashi M, Hiasa K, Zhao Q, Inoue S, Ohtani K, Kitamoto S, Tsuchihashi M, Sugaya T, Charo IF, Kura S, Tsuzuki T, Ishibashi T, Takeshita A, Egashira K. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res 2004; 94: 1203–1210
   PubMed Web of Science ®Google Scholar
• Parissis JT, Venetsanou KF, Kalantzi MV, Mentzikof DD, Karas SM. Serum profiles of granulocyte-macrophage colony-stimulating factor and C-C chemokines in hypertensive patients with or without significant hyperlipidemia. Am J Cardiol 2000; 85: 777–779, A779
   PubMed Web of Science ®Google Scholar
• Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515–581
   PubMed Web of Science ®Google Scholar
• Coccia EM, Stellacci E, Marziali G, Weiss G, Battistini A. IFN-gamma and IL-4 differently regulate inducible NO synthase gene expression through IRF-1 modulation. Int Immunol 2000; 12: 977–985
   PubMed Web of Science ®Google Scholar
• Murata Y, Shimamura T, Hamuro J. The polarization of T(h)1/T(h)2 balance is dependent on the intracellular thiol redox status of macrophages due to the distinctive cytokine production. Int Immunol 2002; 14: 201–212
   PubMed Web of Science ®Google Scholar
• Ozturk H, Ozturk H, Buyukbayram H, Tuncer MC. The effects of exogenous interleukin-4 on hypoxia-induced lung injury. Pediatr Surg Int 2006; 22: 197–201
   PubMedGoogle Scholar
• Michel JB, Sayah S, Guettier C, Nussberger J, Philippe M, Gonzalez MF, Carelli C, Galen FX, Menard J, Corvol P. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation 1990; 81: 1899–1910
   PubMed Web of Science ®Google Scholar
• Dang A, Zheng D, Wang B, Zhang Y, Zhang P, Xu M, Liu G, Liu L. The role of the renin-angiotensin and cardiac sympathetic nervous systems in the development of hypertension and left ventricular hypertrophy in spontaneously hypertensive rats. Hypertens Res 1999; 22: 217–221
   PubMed Web of Science ®Google Scholar
• Kobori H, Ozawa Y, Suzaki Y, Nishiyama A. Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol 2005; 16: 2073–2080
   PubMed Web of Science ®Google Scholar
• Griendling KK, Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept 2000; 91: 21–27
   PubMed Web of Science ®Google Scholar
• Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003; 91: 7A–11A
   PubMed Web of Science ®Google Scholar
• Nava E, Noll G, Luscher TF. Increased activity of constitutive nitric oxide synthase in cardiac endothelium in spontaneous hypertension. Circulation 1995; 91: 2310–2313
   PubMed Web of Science ®Google Scholar
• Chou TC, Yen MH, Li CY, Ding YA. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension 1998; 31: 643–648
   PubMed Web of Science ®Google Scholar
• Cheng PY, Chen JJ, Yen MH. The expression of heme oxygenase-1 and inducible nitric oxide synthase in aorta during the development of hypertension in spontaneously hypertensive rats. Am J Hypertens 2004; 17: 1127–1134
   PubMedGoogle Scholar
• Kimura T, Iwase M, Kondo G, Watanabe H, Ohashi M, Ito D, Nagumo M. Suppressive effect of selective cyclooxygenase-2 inhibitor on cytokine release in human neutrophils. Int Immunopharmacol 2003; 3: 1519–1528
   PubMed Web of Science ®Google Scholar
• Brzozowski T, Konturek PC, Konturek SJ, Kwiecien S, Sliwowski Z, Pajdo R, Duda A, Ptak A, Hahn EG. Implications of reactive oxygen species and cytokines in gastroprotection against stress-induced gastric damage by nitric oxide releasing aspirin. Int J Colorectal Dis 2003; 18: 320–329
   PubMedGoogle Scholar
• Shen K, Sung KL, Whittemore DE, DeLano FA, Zweifach BW, Schmid-Schonbein GW. Properties of circulating leukocytes in spontaneously hypertensive rats. Biochem Cell Biol 1995; 73: 491–500
   PubMed Web of Science ®Google Scholar
• Dorffel Y, Latsch C, Stuhlmuller B, Schreiber S, Scholze S, Burmester GR, Scholze J. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999; 34: 113–117
   PubMed Web of Science ®Google Scholar
• Rodriguez-Iturbe B, Zhan CD, Quiroz Y, Sindhu RK, Vaziri ND. Antioxidant-rich diet relieves hypertension and reduces renal immune infiltration in spontaneously hypertensive rats. Hypertension 2003; 41: 341–346
   PubMed Web of Science ®Google Scholar
• Wu R, Millette E, Wu L, de Champlain J. Enhanced superoxide anion formation in vascular tissues from spontaneously hypertensive and desoxycorticosterone acetate-salt hypertensive rats. J Hypertens 2001; 19: 741–748
   PubMed Web of Science ®Google Scholar
• Ito H, Torii M, Suzuki T. Decreased superoxide dismutase activity and increased superoxide anion production in cardiac hypertrophy of spontaneously hypertensive rats. Clin Exp Hypertens 1995; 17: 803–816
   PubMed Web of Science ®Google Scholar
• Friese RS, Mahboubi P, Mahapatra NR, Mahata SK, Schork NJ, Schmid-Schonbein GW, O'Connor DT. Common genetic mechanisms of blood pressure elevation in two independent rodent models of human essential hypertension. Am J Hypertens 2005; 18: 633–652
   PubMed Web of Science ®Google Scholar
• Terzoli L, Mircoli L, Raco R, Ferrari AU. Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J Cardiovasc Pharmacol 2005; 46: 310–315
   PubMed Web of Science ®Google Scholar
• Yin QF, Xiong Y. Pravastatin restores DDAH activity and endothelium-dependent relaxation of rat aorta after exposure to glycated protein. J Cardiovasc Pharmacol 2005; 45: 525–532
   PubMed Web of Science ®Google Scholar
• Habibi J, Whaley-Connell A, Qazi MA, Hayden MR, Cooper SA, Tramontano A, Thyfault J, Stump C, Ferrario C, Muniyappa R, Sowers JR. Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology 2007; 148: 2181–2188
   PubMedGoogle Scholar
• Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300–305
   PubMed Web of Science ®Google Scholar
• Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61–69
   PubMed Web of Science ®Google Scholar
• Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399–1402
   PubMed Web of Science ®Google Scholar
• Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78–84
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Munoz-Garcia B, Martin-Ventura JL, Lorz C, Diaz C, Hernandez G, Egido J. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes. Circulation 2003; 108: 1506–1513
   PubMedGoogle Scholar
• Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145: 33–43
   PubMed Web of Science ®Google Scholar
• Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T, Sallach S, Endres M, Brocke S, Nitsch R, Zipp F. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003; 197: 725–733
   PubMed Web of Science ®Google Scholar